Intradigm Corporation

12115 Parklawn Drive,
Suite K,
Rockville,
MD 20852
United States of America
Tel: (301)984-0185
Fax: (301)984-0186

Intradigm is a target discovery and drug development company. In the near term, based on our early leadership in achieving therapeutic delivery of RNAi in tumor disease models and our success in identifying new cancer drug targets through our Efficacy-First Discovery™ technology, we will advance these targets into RNAi-based pre-clinical development ourselves, and enter into licenses and collaborations for monoclonal antibody and other therapeutic modalities

Further Information: http://www.intradigm.com

Related news from our archive

Intradigm Announces Issuance of RNA Interference Patent Covering Potent Sirna Sequence
First patent to be issued from among Intradigm’s large collection of pending siRNA sequence patents.

Intradigm Announces Issuance of Key Patent Related to RNAi Therapeutics
Philip Zamore patent covers methods for enhancing RNAi structural features and strengthens Intradigm’s position.

Intradigm Licenses Key Next Generation RNAi Intellectual Property from U of M Medical School
Company continues to fortify position in emerging RNAi industry through addition of small interfering RNA Structural IP.

Intradigm Licences Key Delivery Intellectual Property in the field of RNAi from Massachusetts Institute of Technology
The scope of the licensed technology covers a broad range of biodegradable polymer structures for the delivery of RNAi therapeutics.